NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care. If, after doing this, organisations still wish to consider methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care, they should follow the advice set out in Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance which outlines the approach that should be adopted in circumstances where NICE guidance is unavailable.
NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.
For information about NICE guidance that has been issued or is in development, see the NICE website.
Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults. NICE clinical guideline 140 (2012)
Prucalopride for the treatment of chronic constipation in women. NICE technology appraisal guidance 211 (2010)
NICE is developing the following guidance (details available from the NICE website):
Lubiprostone for the treatment of opioid-induced constipation. NICE technology appraisal. Publication date to be confirmed.